GlassScriptPhysician profile
Genevieve Mcgerald
NPI 1063671113
$1,283.53
in general payments reported to CMS, 2019-2025
11 companies · $156 in 2025
The $156 reported for 2025 was more than what 76% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $56.46 · 2021: $125 · 2022: $189 · 2023: $135 · 2024: $182 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $431.90 | 2019-2022 | |
| Abbvie INC. | $270.72 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $140.08 | 2025 | Dysport |
| Genentech USA, INC. | $109.62 | 2019 | |
| Medtronic USA, INC. | $103.36 | 2019 | |
| Smith+Nephew, INC. | $58.83 | 2023 | Renasys Go V2 Home, Renasys Touch, Collagenase Santyl |
| Bioventus LLC | $54.20 | 2022-2023 | |
| Tactile Systems Technology INC | $52.46 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Kerecis Limited | $36.15 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Hydrofera LLC | $14.20 | 2023 | Hydrofera Blue |
| Janssen Pharmaceuticals, INC | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genevieve Mcgerald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.